(Q38264360)

1 September 2017

1 reference

title

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer (English)

1 reference

1 September 2017

0 references

1 reference

1 reference

3

Tina Vilsbøll

1 reference

1 September 2017

Thor Chalmer

1

1 reference

1 September 2017

Thomas P Almdal

series ordinal

2

1 reference

1 September 2017

Filip K Knop

series ordinal

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

3 November 2014

1 reference

Expert Opinion on Drug Safety

1 September 2017

published in

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

171-180

1 reference

Emerging GLP-1 receptor agonists

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Risk of pancreatitis in patients treated with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.975205

10.1517/14740338.2015.975205

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference